KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Total Current Liabilities (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Total Current Liabilities for 14 consecutive years, with $159.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 20.35% year-over-year to $159.9 million, compared with a TTM value of $159.9 million through Dec 2025, down 20.35%, and an annual FY2025 reading of $159.9 million, down 20.35% over the prior year.
  • Total Current Liabilities was $159.9 million for Q4 2025 at Travere Therapeutics, up from $135.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $200.8 million in Q4 2024 and bottomed at $85.0 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $143.6 million, with a median of $135.4 million recorded in 2023.
  • Peak annual rise in Total Current Liabilities hit 56.3% in 2025, while the deepest fall reached 28.92% in 2025.
  • Year by year, Total Current Liabilities stood at $124.1 million in 2021, then increased by 14.57% to $142.2 million in 2022, then increased by 25.14% to $177.9 million in 2023, then rose by 12.84% to $200.8 million in 2024, then fell by 20.35% to $159.9 million in 2025.
  • Business Quant data shows Total Current Liabilities for TVTX at $159.9 million in Q4 2025, $135.1 million in Q3 2025, and $189.5 million in Q2 2025.